Kiran Mazumdar Shaw, 

Despite a jump in profits in the wake of a successful Syngene initial public offering, parent company Biocon is not in a great position. Brokers recommend booking profits, and few suggest buying at this point. (Interestingly, although out of the timeframe of this ranking, Biocon recently announced its FY16 second-quarter results: a 200% jump in its profits due to a one-time windfall from the Syngene IPO.) Biocon has the biggest portfolio of biologic drugs in the country, but all its global market moves are works in progress. Its generic molecules are in various stages of testing, and its much-touted oral insulin seems to have been buried. That said, Shaw has laid the foundation of several projects (including an insulin factory in Malaysia), which will pay off in the next few years.